Sopharma's top line further deteriorates in Q4'2014 due to Ukraine

Sopharma’s top line further deteriorates in Q4’2014 due to Ukraine

Sopharma

16 April 2015

News

Sopharma

Sopharma’s top line further deteriorates in Q4’2014 due to Ukraine, 3rd largest market of the company – concluded the latest corporate earnings report by ELANA Trading analysts.

Overall FY 2014 unconsolidated sales missed our estimate of 3% drop and are down 6.7% y-o-y to BGN 201.5 m due to 10% drop in exports. Sopharma Q1’15 preliminary results show further deterioration caused also by the January FX turbulence in Russia (Sopharma’s biggest market). Preliminary Q1’15 top line decline settled at 21% y-o-y as Russian market returned to normal in February and March and sales in Bulgaria (2nd biggest market) jumped 20% up.

Find out in detail in Sopharma (3JR BU) 2014 financial results report by ELANA Trading analysts

More about Sopharma in the corporate profile report

ELANA Trading has a 29 years of history on financial markets, offering a wide range of services and markets. ELANA Trading quality service has been recognized by 24 industry awards. The broker is part of the international brokers’ network of US Auerbach Grayson & Co. since 1998 and maintains long-term partnerships with a lot of international financial institutions.

ELANA Trading is part of ELANA group - one of the largest groups in the non-banking financial sector in Bulgaria.

Contacts

Dimitar Georgiev
Head of Trading
Phone: +359 (2) 81 000 25
Email: georgievd@elana.net

Tatyana Puncheva-Vasileva
Head of Research
Phone: +359 (2) 81 000 24
Email: vasileva@elana.net

Contacts

Sopharma Business Towers,
Tower B, Floors 12-13,
5, Lachezar Stanchev St,
1797 Sofia, Bulgaria

Phone: +359 (2) 81 000 25
Phone: +359 (2) 81 000 26
Email: bgtrader@elana.net

Disclaimer: This website represents ELANA Trading with the sole purpose to provide information. The data published on the website is not provided to be used as a background for specific investment decisions. No publication of ELANA Trading should be construed as an offer (or solicitation of an offer) to U.S. persons to buy or sell financial instruments or any financial product, make any investment or participate in any particular trading strategy (collectively “Offers”). No Publication of ELANA Trading should be construed as an Offer (or solicitation of an offer) in any jurisdiction in which such Offer would be illegal. Any such perceived Offer will not be honoured by ELANA Trading.